Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

VRAX Virax Biolabs Group Limited Ordinary Shares
$0.27 0.00% 0.00
Notify me if price changes either direction
Interactive Brokers Logotype

Buy VRAX stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 2.1M
Enterprise value -1286532
Trailing PE -0.17469135331519
Forward PE -1.1791667
PEG Ratio -1.1791667
Enterprise to EBITDA 0.232
Enterprise to revenue -430.855
Price to book MRQ 0.34852216
Price to sales TTM 703.5603

Financials

Fiscal Year Ends 2025-03-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 2986
EBITDA -5556497
Diluted EPS TTM -1.22
Total Cash (MRQ) 3.4M
Current ratio (MRQ) 11.354
Operating Cash Flow (TTM) -5405240

VRAX trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent VRAX News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.